

Treatment-Experienced Depression

TABLE 143: DEPRESSION TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR48 q8	PR48	0.67 (0.35 to 1.26)	-4.33 (-9.68 to 3.10)
SIM12 PR48		0.91 (0.46 to 1.77)	-1.15 (-8.07 to 9.09)
B32 PR36-48 RGT		0.95 (0.42 to 1.99)	-0.68 (-8.28 to 11.58)
SOF12 + RBV12		0.46 (0.14 to 1.31)	-7.01 (-12.85 to 3.86)
SOF24 + RBV24		0.17 (0.01 to 0.99)	-10.65 (-15.36 to -0.15)
SOF12 + LDV12 + RBV12		0.64 (0.22 to 1.65)	-4.72 (-11.38 to 7.87)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.27 (0.07 to 0.93)	-9.42 (-14.25 to -0.89)
DCV24 + ASU24		0.11 (0.02 to 0.50)	-11.49 (-15.62 to -5.97)
SIM12 PR48	T12 PR48 q8	1.36 (0.70 to 2.65)	3.09 (-3.58 to 11.69)
B32 PR36-48 RGT		1.43 (0.50 to 3.68)	3.64 (-6.91 to 16.33)
SOF12 + RBV12		0.69 (0.18 to 2.27)	-2.64 (-11.20 to 8.40)
SOF24 + RBV24		0.25 (0.02 to 1.69)	-6.25 (-14.15 to 4.74)
SOF12 + LDV12 + RBV12		0.95 (0.30 to 2.79)	-0.40 (-9.00 to 12.05)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.40 (0.12 to 1.15)	-4.95 (-10.61 to 1.31)
DCV24 + ASU24		0.17 (0.03 to 0.84)	-7.06 (-14.57 to -1.05)
B32 PR36-48 RGT	SIM12 PR48	1.04 (0.38 to 2.70)	0.44 (-11.70 to 13.58)
SOF12 + RBV12		0.51 (0.13 to 1.59)	-5.67 (-16.41 to 5.27)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24		0.18 (0.01 to 1.25)	-9.38 (-19.73 to 2.17)
SOF12 + LDV12 + RBV12		0.71 (0.23 to 2.00)	-3.37 (-14.26 to 9.07)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.30 (0.07 to 1.06)	-8.14 (-17.70 to 0.56)
DCV24 + ASU24		0.12 (0.02 to 0.61)	-10.28 (-20.20 to -3.13)
SOF12 + RBV12	B32 PR36-48 RGT	0.49 (0.18 to 1.15)	-5.95 (-15.95 to 1.56)
SOF24 + RBV24		0.18 (0.02 to 0.88)	-9.53 (-20.44 to -1.25)
SOF12 + LDV12 + RBV12		0.68 (0.19 to 2.25)	-3.96 (-17.37 to 10.09)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.28 (0.06 to 1.31)	-8.61 (-21.10 to 2.39)
DCV24 + ASU24		0.12 (0.03 to 0.41)	-10.66 (-21.00 to -4.61)
SOF24 + RBV24	SOF12 + RBV12	0.37 (0.03 to 2.42)	-3.39 (-13.51 to 5.95)
SOF12 + LDV12 + RBV12		1.38 (0.34 to 6.41)	2.22 (-9.25 to 15.23)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.59 (0.10 to 3.41)	-2.29 (-13.09 to 7.00)
DCV24 + ASU24		0.25 (0.05 to 1.20)	-4.32 (-14.15 to 0.64)
SOF12 + LDV12 + RBV12	SOF24 + RBV24	3.88 (0.50 to 55.73)	5.76 (-5.31 to 18.37)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.63 (0.16 to 26.24)	1.20 (-9.19 to 10.16)
DCV24 + ASU24		0.67 (0.08 to 9.59)	-0.61 (-10.57 to 3.98)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF12 + LDV12 + RBV12	0.43 (0.08 to 2.02)	-4.53 (-17.15 to 4.68)
DCV24 + ASU24		0.17 (0.03 to 1.01)	-6.69 (-18.97 to 0.05)
DCV24 + ASU24	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.41 (0.05 to 3.19)	-1.94 (-10.56 to 3.45)
Random effect model	Residual deviance	23.48 vs. 24 data points	
	Deviance information criteria	135.299	
Fixed effect model	Residual deviance	23.98 vs. 24 data points	
	Deviance information criteria	135.244	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.